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Introduction: We conducted an external validation study to examine the correlation of a previously published
claims-based index for rheumatoid arthritis severity (CIRAS) with disease activity score in 28 joints calculated by
using C-reactive protein (DAS28-CRP) and the multi-dimensional health assessment questionnaire (MD-HAQ)
physical function score.
Methods: Patients enrolled in the Brigham and Women’s Hospital Rheumatoid Arthritis Sequential Study (BRASS)
and Medicare were identified and their data from these two sources were linked. For each patient, DAS28-CRP
measurement and MD-HAQ physical function scores were extracted from BRASS, and CIRAS was calculated from
Medicare claims for the period of 365 days prior to the DAS28-CRP measurement. Pearson correlation coefficient between
CIRAS and DAS28-CRP as well as MD-HAQ physical function scores were calculated. Furthermore, we considered several
additional pharmacy and medical claims-derived variables as predictors for DAS28-CRP in a multivariable linear
regression model in order to assess improvement in the performance of the original CIRAS algorithm.
Results: In total, 315 patients with enrollment in both BRASS and Medicare were included in this study. The
majority (81%) of the cohort was female, and the mean age was 70 years. The correlation between CIRAS and
DAS28-CRP was low (Pearson correlation coefficient = 0.07, P = 0.24). The correlation between the calculated
CIRAS and MD-HAQ physical function scores was also found to be low (Pearson correlation coefficient = 0.08,
P = 0.17). The linear regression model containing additional claims-derived variables yielded model R2 of 0.23,
suggesting limited ability of this model to explain variation in DAS28-CRP.
Conclusions: In a cohort of Medicare-enrolled patients with established RA, CIRAS showed low correlation with
DAS28-CRP as well as MD-HAQ physical function scores. Claims-based algorithms for disease activity should be
rigorously tested in distinct populations in order to establish their generalizability before widespread adoption.Introduction
One of the most important confounders in observational
studies of patients with rheumatoid arthritis (RA) is disease
severity. Owing to large size and relative ease of access,
health-care utilization databases have been increasingly
used to study various treatment outcomes in RA [1-4].
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stated.in these databases, and hence studies conducted using these
data are prone to residual confounding by disease severity.
To address this problem, Ting et al. [5] developed an algo-
rithm to create a claims-based index for rheumatoid arth-
ritis severity (CIRAS) by using numerous variables from
claims. In their original article, Ting et al. [5] used RA
records-based index of severity (RARBIS), which was con-
structed by using ratings by a Delphi panel on potential
markers of RA severity commonly found in medical
charts, to demonstrate the validity of CIRAS and reported
moderate correlation between the medical records and
claims-based indices.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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search [6-8], CIRAS has not been validated against a
clinical marker of RA severity until now. RA severity is a
complex concept that depends on a combination of dis-
ease activity, physical function impairment, and physical
damage to the joints. Clinically accepted measures for
accurately determining RA severity that include all of
these aspects are scarce. However, the disease activity
score in 28 joints calculated by using C-reactive protein
(DAS28-CRP) [9] is commonly used to evaluate treat-
ment success and to guide treatment selection in pa-
tients with RA [10]. Therefore, in the absence of a
standard clinical measure for RA severity, we selected
the disease activity measure DAS28-CRP to validate the
claims-based severity measure CIRAS in this external
validation study using data from the Brigham and
Women’s Hospital Rheumatoid Arthritis Sequential
Study (BRASS) linked to Medicare claims. Furthermore, we
examined the correlation between the multi-dimensional
health assessment questionnaire (MD-HAQ) [11] physical
function scores and CIRAS.
Methods
The BRASS registry is a single-center, prospective, obser-
vational cohort of 1,350 patients with a rheumatologist-
verified diagnosis of RA. For the subjects enrolled in this
registry, data on patient-reported items, including demo-
graphics, lifestyle factors, medication use, and quality-of-
life scales, as well as physician-reported items such as
DAS28-CRP, extra-articular manifestations, and medica-
tion changes are collected during annual follow-up visits.
For this study, we identified BRASS patients who were
also enrolled in Medicare between 2006 and 2010, and
linked their data from these two sources. Of these sub-
jects, we further identified those with at least one valid
DAS28-CRP measurement in BRASS after 365 days of
continuous enrollment in Medicare. The algorithm pro-
posed by Ting et al. [5] was implemented by using
Medicare claims data in the period of 365 days immedi-
ately prior to the DAS28-CRP measurement date to cal-
culate the CIRAS for these patients. Pearson correlation
coefficients between the calculated CIRAS and DAS28-
CRP were calculated. We also analyzed MD-HAQ phys-
ical function scores measured on the same day as
DAS28-CRP for these patients and calculated Pearson
correlation coefficients between the calculated CIRAS
and MD-HAQ. Personal identifiers were removed from
the dataset before the analysis to protect subject confi-
dentiality. Patient informed consent was, therefore, not
required. This study was approved by the Brigham and
Women’s Hospital’s Institutional Review Board.
Furthermore, we identified several other potential pre-
dictors of RA severity, which were not part of the ori-
ginal CIRAS, from medical and pharmacy claims in asubset of patients who had Medicare part D enrollment
for the 365-day period prior to the DAS28 measurement
date in order to improve the algorithm for CIRAS. These
variables included rheumatoid lung involvement, hand
surgery, tuberculin test ordered, and anti-cyclic citrulli-
nated peptide (CCP) test ordered, steroid use, opioid use,
non-steroidal anti-inflammatory drug (NSAID) use, num-
ber of non-biologic disease-modifying anti-rheumatoid
drugs (DMARDs) used, and biologic DMARD use. A mul-
tivariable linear regression model was built by using
DAS28-CRP as the outcome and these claims-derived var-
iables as predictors. Adjusted correlations between the
predictors and the outcome were reported as partial R2
values. Full model R2 was reported as a measure of the
overall performance of this model.
Results
We located 368 patients who were enrolled in both
BRASS and Medicare. We then excluded 53 patients
who did not have at least one valid DAS28-CRP mea-
sured in BRASS after 365 days of continuous enrollment
in Medicare, leaving 315 patients with sufficient baseline
data for calculation of CIRAS. Of these 315 patients, the
majority (81%) were females. The mean (standard devi-
ation) age of the cohort was 70 (10) years. The median
(interquartile range) DAS28-CRP and CIRAS were 3.3
(2.3 to 4.6) and 4.4 (3.7 to 5.1), respectively. Other pa-
tient characteristics used for CIRAS calculation are sum-
marized in Table 1. The correlation between the
calculated CIRAS and DAS28-CRP was found to be poor
(Pearson correlation coefficient = 0.07, P = 0.24). The
correlation between the calculated CIRAS and MD-
HAQ physical function scores was also found to be low
(Pearson correlation coefficient = 0.08, P = 0.17).
Furthermore, we identified a subgroup of 119 patients
who had at least 1 year of Medicare part D enrollment im-
mediately prior to the DAS28-CRP measurement date.
The linear regression model containing additional claims-
derived variables along with the variables originally pro-
posed by Ting et al. [5] yielded model R2 of 0.23, suggesting
limited ability of this model to explain variation in DAS28-
CRP. Among some of the most influential predictors in this
model were biologic DMARD use, opioid use, tuberculin
test ordered, and number of non-biologic DMARDs used
in the prior year (Table 2).
Discussion
In this validation study using data from an external co-
hort of Medicare-enrolled patients with an established
diagnosis of RA, the previously published algorithm to
approximate RA severity by using claims-based variables
had poor correlation with DAS28-CRP and MD-HAQ.
Adding more variables derived from both medical and
pharmacy claims as predictors in a linear regression
Table 1 Characteristics of rheumatoid arthritis patients
included in the external validation study
Variable Number
(percentage)
(Total number = 315)
Components of the algorithm for calculating CIRAS
Age in years, mean (SD) 70 (10)
Females 255 (81.0)
Inflammatory marker tests ordered 230 (73.0)
Rehabilitation visits (physical or
occupational therapy visits)
75 (23.8)
Rheumatoid factor test ordered 17 (5.4)














Number of rheumatologist visits
None 51 (16.2)
1 to 4 220 (69.8)
>4 44 (14.0)
Rheumatoid arthritis severity variables
CIRAS, mean (SD) 4.4 (1.2)
DAS28-CRP, mean (SD) 3.5 (1.5)
MD-HAQ physical function score, mean (SD) 2.5 (1.9)
Data are from the Brigham and Women’s Hospital Rheumatoid Arthritis
Sequential Study linked with Medicare claims (2006 to 2010). CIRAS, claims-based
index for rheumatoid arthritis severity; DAS28-CRP, disease activity score in 28
joints calculated by using C-reactive protein; MD-HAQ, multi-dimensional health
assessment questionnaire; SD, standard deviation.
Table 2 Adjusted correlations between additional
claims-based variables related to rheumatoid arthritis
severity and DAS28-CRP
Variable Partial R2
Original variables included in the algorithm to calculate CIRASa
Age 0.001
Gender 0.001
Inflammatory marker tests ordered 0.004
Rehabilitation visits (physical or occupational therapy visits) 0.0001
Rheumatoid factor test ordered 0.003
Platelet counts ordered 0.03
Number of chemistry panels ordered 0.001
Number of rheumatologist visits 0.004
Additional medical claims-based variables
Rheumatoid lung involvement 0.005
Hand surgery 0.006
Tuberculin test ordered 0.05
Anti-CCP test ordered 0.005




Number of non-biologic DMARDs used 0.03
Biologic DMARD use 0.05
Model R2 0.23
Data are from the Brigham and Women’s Hospital Rheumatoid Arthritis
Sequential Study linked with Medicare claims (2006 to 2010). aA subsample of
patients with pharmacy claims available (119 out of 315) was used to calculate
these R2 values. In this subsample, none of the patients had a Felty’s
syndrome diagnosis. Therefore, that variable is not reported in this table. All of
the variables were measured in the period of 365 days immediately prior to the
DAS28-CRP (disease activity score in 28 joints calculated by using C-reactive
protein) measurement date. CIRAS, claims-based index for rheumatoid arthritis
severity; CCP, cyclic citrullinated peptide; DMARD, disease-modifying
anti-rheumatic drug; NSAID, non-steroidal anti-inflammatory drug.
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this algorithm in predicting DAS28-CRP.
Several potential differences between this external val-
idation study and the original study in which Ting et al.
[5] developed CIRAS may explain the poor performance
of CIRAS in this cohort. First, it must be noted that
CIRAS was validated against a medical records-based RA
severity index (RARBIS) in the original study and that the
correlation between the two indices was found to be mod-
erate (Spearman correlation coefficient = 0.51). RARBIS it-
self has been shown to correlate only moderately withDAS28 (Spearman correlation coefficient = 0.41) [12]. The
majority of the clinical parameters measured through
RARBIS, including patients’ functional status, arthritis
flares, x-ray results, and laboratory results, are not cap-
tured in claims and hence in CIRAS. Therefore, the poor
performance of CIRAS against DAS28-CRP may simply re-
flect the inability to account for these important clinical
parameters. Next, important differences between the
current cohort and the CIRAS derivation cohort, including
sizable gender differences (81% versus 9% females), differ-
ences in the disease activity, and differences in health-care
utilization patterns, may help explain the poor perform-
ance of CIRAS in this validation cohort.
CIRAS has been used in observational studies of RA
treatments in the past mainly to control for confounding
by disease activity. Two prior studies used CIRAS as a co-
variate in their regression models for the outcome [6,7].
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diction of a disease risk score (infection score) and strati-
fied analysis based on this disease risk score to account for
measured confounding [8]. Findings from our study show
poor correlation between CIRAS and DAS28-CRP (RA ac-
tivity measure, which often drives treatment selection) as
well as MD-HAQ (patient physical function score, which
may be indicative of frailty and hence may be an import-
ant confounder). These findings suggest that CIRAS may
not accurately approximate disease activity or frailty in ob-
servational studies of RA treatments using insurance
claims data. Given this poor correlation between CIRAS
and important confounders unmeasured in health-care
claims data, future research should be considered to critic-
ally evaluate the benefit of using CIRAS as a tool for con-
founding control.
Another important contribution of our study is that it
highlights the importance of external validation of claims-
based algorithms. Two prior studies have attempted to
build algorithms predicting RA severity. Wolfe et al. [13]
used data on the type and number of DMARDs used by
the patients in the National Data Bank for Rheumatic
Diseases to predict their RA severity and found subopti-
mal performance of these variables in predicting RA sever-
ity as measured by a patient activity scale. Baser et al. [14]
used Veterans Health Administration claims to build a se-
verity index for rheumatoid arthritis (SIFRA) and reported
moderate correlations with the CIRAS. Before widespread
adoption of these indices, broad testing is critical to deter-
mine their appropriateness in different databases.
Conclusions
Our study reported a low correlation between the previ-
ously proposed CIRAS and DAS28-CRP as well as MD-
HAQ physical function scores, suggesting that CIRAS
may not approximate RA disease activity or frailty reliably
in observational cohorts. Claims-based algorithms for clin-
ical disease activity should be rigorously tested in distinct
populations in order to establish their generalizability.
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